Chinese Journal of Tissue Engineering Research ›› 2010, Vol. 14 ›› Issue (18): 3258-3261.doi: 10.3969/j.issn.1673-8225.2010.18.007

Previous Articles     Next Articles

Hepatitis B virus recurrence following liver transplantation: A 19-case report in the same treatment center within 43 months

Yu Ru-sheng, Jiang Yi, Lü Li-zhi, Cai Qiu-cheng   

  1. Department of Hepatobiliary Surgery, Fuzhou General Hospital of Nanjing Military Area Command of Chinese PLA, Clinical Medical College of Fujian Medical University, Fuzhou   350025, Fujian Province, China
  • Online:2010-04-30 Published:2010-04-30
  • Contact: 江 艺，博士生导师，福建医科大学福总临床医学院肝胆外科，福建省福州市 350025。 jiangyi183@yahoo.com.cn
  • About author:Yu Ru-sheng★, Master, Physician, Department of Hepatobiliary Surgery, Fuzhou General Hospital of Nanjing Military Area Command of Chinese PLA, Clinical Medical College of Fujian Medical University, Fuzhou 350025, Fujian Province, China
  • Supported by:

     the Eleventh Five-Year Plan Project of Nanjing Military Area Command of Chinese PLA, No. 06Z46*

PDF

305

Abstract:

BACKGROUND: Hepatitis B virus (HBV) recurrence following liver transplantation has been difficultly treated, and antiviral therapy following HBV recurrence has been less reported yet.
OBJECTIVE: To investigate the antiviral therapy using Adefovir + Lamivudine + anti-hepatis B immunoglobulin on liver functional improvement following liver transplantation.
METHODS: A total of 208 cases with hepatitis B-related end-stage liver disease following liver transplantation were selected from Liver Transplantation Center of Fuzhou General Hospital of Nanjing Military Area Command of Chinese PLA from January 2005 to October 2008. All patients were treated with Lamivudine + anti-hepatis B immunoglobulin so as to prevent from HBV recurrence. At 6-43 months after following up, HBV recurrence was found in 19 cases, including 13 with positive HBeAg and 8 with YMDD mutation. The 19 patients were treated with Adefovir based on the application of Lamivudine + anti-hepatis B immunoglobulin.
RESULTS AND CONCLUSION: At 12, 24, and 48 weeks after treatment, DNA and glutamic-pyruvic transaminase of 19 cases were significantly decreased (P < 0.01). After 48-week treatment, recovery rate of glutamic-pyruvic transaminase, negativity rate of HBeAg, and negativity rate of HBV DNA were 84.1%, 76.92%, and 78.9%, respectively. The results demonstrated that the application of Adefovir + Lamivudine + anti-hepatis B immunoglobulin effectively inhibited viral replication and prevented HBV recurrence following liver transplantation.